Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Recruiting

Phase 2

Ipilimumab & NivolumabIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT03646617

Conditions

Metastatic Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Hypofractionated Radiation Therapy (HFRT)

Nivolumab

Ipilimumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2025-08-13.